Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SRDAN VERSTOVSEK and PRITHVIRAJ BOSE.
SRDAN VERSTOVSEK
Connection Strength
23.204
PRITHVIRAJ BOSE
  1. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
    View in: PubMed
    Score: 0.973
  2. Avapritinib for Systemic Mastocytosis. Expert Rev Hematol. 2021 08; 14(8):687-696.
    View in: PubMed
    Score: 0.791
  3. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):641-649.
    View in: PubMed
    Score: 0.785
  4. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel). 2020 Oct 09; 12(10).
    View in: PubMed
    Score: 0.747
  5. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere. 2020 Aug; 4(4):e424.
    View in: PubMed
    Score: 0.736
  6. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma. 2020 08; 61(8):1797-1809.
    View in: PubMed
    Score: 0.723
  7. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020 Feb; 111(2):192-199.
    View in: PubMed
    Score: 0.699
  8. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019; 10:2040620719870052.
    View in: PubMed
    Score: 0.692
  9. MF management. Hemasphere. 2019 Jun; 3(Suppl).
    View in: PubMed
    Score: 0.684
  10. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol. 2019 01 24; 20(1):5.
    View in: PubMed
    Score: 0.664
  11. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
    View in: PubMed
    Score: 0.662
  12. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019; 60(9):1176-1185.
    View in: PubMed
    Score: 0.661
  13. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
    View in: PubMed
    Score: 0.648
  14. Management of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep. 2018 06; 13(3):164-172.
    View in: PubMed
    Score: 0.635
  15. SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):1-12.
    View in: PubMed
    Score: 0.617
  16. Ruxolitinib for essential thrombocythemia? Oncoscience. 2017 Nov; 4(11-12):148-149.
    View in: PubMed
    Score: 0.610
  17. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S43-S52.
    View in: PubMed
    Score: 0.596
  18. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 07 13; 130(2):115-125.
    View in: PubMed
    Score: 0.590
  19. Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017 Jun; 26(6):723-734.
    View in: PubMed
    Score: 0.590
  20. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw. 2016 12; 14(12):1613-1624.
    View in: PubMed
    Score: 0.572
  21. Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016 Dec; 17(18):2375-2389.
    View in: PubMed
    Score: 0.570
  22. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016 Dec; 25(12):1393-1403.
    View in: PubMed
    Score: 0.569
  23. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S105-13.
    View in: PubMed
    Score: 0.559
  24. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 2016 Mar 01; 122(5):681-92.
    View in: PubMed
    Score: 0.537
  25. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial. Haematologica. 2024 06 01; 109(6):1977-1983.
    View in: PubMed
    Score: 0.241
  26. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024; 15:20406207241229588.
    View in: PubMed
    Score: 0.236
  27. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
    View in: PubMed
    Score: 0.230
  28. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):523-530.
    View in: PubMed
    Score: 0.229
  29. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments. Cancers (Basel). 2023 Jun 24; 15(13).
    View in: PubMed
    Score: 0.225
  30. The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.
    View in: PubMed
    Score: 0.224
  31. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 06; 64(6):1063-1081.
    View in: PubMed
    Score: 0.223
  32. Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother. 2023 Jun; 24(8):901-912.
    View in: PubMed
    Score: 0.223
  33. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.
    View in: PubMed
    Score: 0.211
  34. Disease Modification in Myelofibrosis: An Elusive Goal? J Clin Oncol. 2022 04 10; 40(11):1147-1154.
    View in: PubMed
    Score: 0.204
  35. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.
    View in: PubMed
    Score: 0.204
  36. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022 01 19; 15(1):7.
    View in: PubMed
    Score: 0.204
  37. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.
    View in: PubMed
    Score: 0.203
  38. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):210-223.
    View in: PubMed
    Score: 0.200
  39. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.199
  40. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.
    View in: PubMed
    Score: 0.194
  41. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol. 2021; 144(5):484-499.
    View in: PubMed
    Score: 0.194
  42. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.
    View in: PubMed
    Score: 0.190
  43. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.
    View in: PubMed
    Score: 0.184
  44. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020 Jun; 29(6):525-536.
    View in: PubMed
    Score: 0.184
  45. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.179
  46. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019 08 13; 3(15):2264-2271.
    View in: PubMed
    Score: 0.172
  47. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019 08; 14(4):310-327.
    View in: PubMed
    Score: 0.172
  48. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866.
    View in: PubMed
    Score: 0.167
  49. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263.
    View in: PubMed
    Score: 0.155
  50. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep. 2018 01; 6(1):155-161.
    View in: PubMed
    Score: 0.153
  51. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.
    View in: PubMed
    Score: 0.149
  52. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116.
    View in: PubMed
    Score: 0.148
  53. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res. 2017 07; 58:14-22.
    View in: PubMed
    Score: 0.146
  54. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res. 2017 06; 57:85-88.
    View in: PubMed
    Score: 0.146
  55. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738.
    View in: PubMed
    Score: 0.145
  56. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol. 2017 Feb; 176(3):352-364.
    View in: PubMed
    Score: 0.143
  57. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871.
    View in: PubMed
    Score: 0.140
  58. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
    View in: PubMed
    Score: 0.060
  59. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.052
  60. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.
    View in: PubMed
    Score: 0.052
  61. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. 2022 Oct; 40(4):491-504.
    View in: PubMed
    Score: 0.052
  62. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.
    View in: PubMed
    Score: 0.051
  63. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
    View in: PubMed
    Score: 0.051
  64. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.
    View in: PubMed
    Score: 0.049
  65. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.049
  66. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.049
  67. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.048
  68. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
    View in: PubMed
    Score: 0.048
  69. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021 06; 193(5):1004-1008.
    View in: PubMed
    Score: 0.048
  70. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411.
    View in: PubMed
    Score: 0.048
  71. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.046
  72. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.046
  73. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
    View in: PubMed
    Score: 0.045
  74. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.044
  75. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug; 37(3):240-252.
    View in: PubMed
    Score: 0.043
  76. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
    View in: PubMed
    Score: 0.041
  77. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.040
  78. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.
    View in: PubMed
    Score: 0.039
  79. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.038
  80. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.